- Home
- PLX vs FHTX Comparison
PLX vs FHTX Comparison
Compare PLX & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLX | FHTX |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 173.4M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PLX | FHTX |
|---|---|---|
| Price | $2.75 | $1.90 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.17 |
| AVG Volume (30 Days) | 767.5K | ★ 1.1M |
| Earning Date | 08-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | $30,909,000.00 |
| Revenue This Year | $55.77 | N/A |
| Revenue Next Year | N/A | $15.98 |
| P/E Ratio | $10.30 | ★ N/A |
| Revenue Growth | N/A | ★ 36.75 |
| 52 Week Low | $1.60 | $1.79 |
| 52 Week High | $3.19 | $7.61 |
Technical Indicators
Market Signals| Indicator | PLX | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 15.48 |
| Support Level | $2.59 | $1.79 |
| Resistance Level | $2.85 | $5.35 |
| Average True Range (ATR) | 0.09 | 0.27 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 73.83 | 5.10 |
Price Performance
Historical ComparisonAbout PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.